Bringing CAR T Closer to Home

CAR T Vision aims to widen access to cell therapy by expanding community-based delivery, easing operational barriers, and building sustainable funding models

October 13, 2026
8 min

The Medicine Maker

Overview

CAR T Vision is a multidisciplinary coalition seeking to double the proportion of eligible patients receiving CAR T-cell therapy by 2030. Its Vision to Action Blueprint is intended to coordinate efforts addressing awareness and education, treatment capacity, and sustainable funding and reimbursement, including support for safe delivery in community settings.

Background

CAR T-cell therapy has expanded across cancer indications, while the source describes persistent barriers to access, including geography, limited treatment-center capacity, cost, and administrative complexity. The article reports that only a small minority of eligible patients in the United States currently receive CAR T therapy. It also anticipates that additional therapies and indications will increase the number of eligible patients, placing pressure on the existing delivery system. CAR T Vision was formed to bring stakeholders together and address access barriers that existing initiatives may be tackling separately.

Data Highlights

Measure or initiative	Source-reported detail
CAR T Vision access goal	Double the proportion of eligible patients treated with CAR T therapy by 2030.
Priority areas	Awareness and education; capacity; sustainable funding and reimbursement.
Current access	The interview describes only a small minority of eligible patients in the United States as having access to CAR T therapy; no percentage is provided.
Community care context	The interview states that the majority of cancer patients in the United States receive care in their community.

Key Findings

CAR T Vision brings together patient advocacy groups, medical societies, academic and community treatment centers, and policy, health technology assessment, and other subject-matter experts.
The coalition's stated goal is to double the proportion of eligible patients receiving CAR T therapy by 2030.
The Vision to Action Blueprint is described as a resource for identifying access barriers and actions to address them, with priorities spanning education, capacity, and sustainable funding and reimbursement.
The interview identifies a limited number of treatment centers, travel distance, transportation, and caregiver support as barriers that can affect treatment access.
Community oncology practices may deliver CAR T and manage side effects, while collaboration with acute-care providers remains important for adverse events that cannot be managed in the community.
The related article describes CAR T Vision as launched in early 2025 with initial funding and support from Gilead and Kite.

Clinical Implications

The interview describes community-based CAR T delivery as one approach to bringing treatment closer to patients, while emphasizing the importance of infrastructure and collaboration with acute-care providers for adverse events. The Blueprint is presented as a cross-sector resource for identifying barriers and coordinating actions; the source does not provide specific implementation protocols or outcome data.

Conclusion

CAR T Vision's Blueprint seeks to coordinate efforts to expand access as eligible populations and indications grow. The source frames community delivery, alongside attention to capacity, education, and sustainable reimbursement, as part of that access effort.